Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H ( (HK:2252) ) just unveiled an update.
Shanghai MicroPort MedBot reported a significant increase in revenue by 77% to RMB175.7 million for the first half of 2025, driven by the rapid commercialization of its surgical robots, particularly in overseas markets. Despite a net loss of RMB114.9 million, the company successfully narrowed its losses by 58.9% compared to the previous year, attributed to strategic cost reductions and efficiency improvements, alongside a decrease in net free cash outflow by 42.8% due to reduced net loss and completion of fixed asset investments.
The most recent analyst rating on (HK:2252) stock is a Hold with a HK$19.10 price target. To see the full list of analyst forecasts on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H stock, see the HK:2252 Stock Forecast page.
More about Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
Shanghai MicroPort MedBot (Group) Co., Ltd. is a joint stock company based in China, specializing in the development and commercialization of surgical robots. The company’s primary products include the Toumai Laparoscopic Surgical Robot, SkyWalker Orthopedic Surgical Robot, and R-ONE Vascular Interventional Surgical Robot, with a strong market focus on both domestic and international regions.
Average Trading Volume: 7,600,445
Technical Sentiment Signal: Buy
Current Market Cap: HK$21B
See more data about 2252 stock on TipRanks’ Stock Analysis page.